Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 50.44% | 28.98% | -183.89% | -380.79% | -607.86% |
| Total Depreciation and Amortization | 13.65% | 17.36% | 44.22% | 65.09% | 63.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.46% | 23.66% | 16.09% | 4.15% | -4.77% |
| Change in Net Operating Assets | 173.39% | 182.16% | 104.00% | 60.19% | 73.68% |
| Cash from Operations | 380.57% | 1,576.55% | 1,284.50% | 180.83% | 143.18% |
| Capital Expenditure | 24.16% | 57.32% | 52.95% | 50.28% | 52.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 98.96% | 99.47% | 99.47% | 99.47% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.68% | 111.55% | 144.57% | 143.73% | 4.43% |
| Cash from Investing | 11.63% | 105.47% | 131.36% | 130.90% | -67.94% |
| Total Debt Issued | -- | -53.20% | -53.37% | -53.27% | -- |
| Total Debt Repaid | 1.42% | -17.47% | -64.99% | -184.69% | -1,030.00% |
| Issuance of Common Stock | -18.18% | 1.07% | 18.91% | 37.98% | 19.15% |
| Repurchase of Common Stock | 50.27% | -409.22% | -3,491.71% | -16,689.85% | -21,225.36% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 62.16% | -991.63% | -1,098.01% | -880.71% | -858.43% |
| Foreign Exchange rate Adjustments | 413.63% | 234.91% | 255.15% | 139.82% | 41.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.76% | 99.25% | 121.24% | 115.97% | -102.51% |